STUDIES
id.DRIVE carries out different studies under a common data collection: viral respiratory surveillance study, COVID-19 Vaccine Effectiveness Study (CVE) and RSV Vaccine Effectiveness Study (to start this fall).
The common data collection started on 26 July 2024. Sites are getting activated to transition from CVE to common data collection over the summer.
Study #1: COVID-19 Vaccine Effectiveness Study
This study uses a multi-country hospital-based test negative case control design. Patient recruitment was initiated in September 2021 and by June 18th, over 15,297 patients were recruited across 21 hospitals in 5 European countries.
The study was initiated on request by AstraZeneca and Janssen and was later joined by Novavax, Valneva and Pfizer to fulfil regulatory commitments. The data collection is still ongoing.
The study is registered on the EMA Real-World Data Catalogue under “id.DRIVE (former COVIDRIVE) study of brand-specific COVID-19 vaccine effectiveness against severe COVID-19 disease in Europe”.
This is a multi-country hospital-based study which monitors viral respiratory infections in adults hospitalised for severe acute respiratory infection (SARI) and started 26 July 2024.
The study is registered on the EMA Real-World Data Catalogue under “id.DRIVE surveillance study of respiratory pathogens in adults hospitalised for severe acute respiratory infection (SARI) across Europe”.
Study #3: RSV Vaccine Effectiveness Study
This study will use a multi-country hospital-based test negative case control design. This study is in setup phase and will start in fall 2024.
The study is registered on the EMA Real-World Data Catalogue under “id.DRIVE study of brand-specific respiratory syncytial virus (RSV) vaccine effectiveness in Europe”.